ribonuclease A family member 13 (inactive)Genealiases: HEL-S-86p · RAL1
Q-omics provides the consensus-scored RNASE13 profile across patient tissues and cancer cell-line models. RNASE13 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, RNASE13 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, RNASE13 RNA expression shows 12,366 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight STAD, KIRC, and THYM as cancer lineages where RNASE13 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNASE13 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNASE13 survival associations across molecular data types. RNASE13 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNASE13 RNA expression–survival associations across cancer types. High RNASE13 expression shows unfavorable associations in STAD, KIRC and DLBC, but favorable associations in HNSC, MESO and READ. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify STAD as the clearest survival context for RNASE13 RNA expression.
This table summarizes RNASE13 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RNASE13. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNASE13 shows lower tumor expression in KIRC, LUSC, BRCA, LUAD and HNSC and higher tumor expression in LIHC. The KIRC box plot shows higher RNASE13 RNA expression in normal versus tumor tissue (log2 FC = −0.104, t-test p < 0.001).
This table shows molecular features associated with RNASE13 in patient tissues and cancer cell lines. In patient samples, RNASE13 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, RNASE13 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and UPPER_AERODIGESTIVE_TRACT.
